New Zealand’s largest producer of medicinal cannabis, Helius Therapeutics, has launched in the Australian market under the brand HTL. On the 3rd anniversary of the launch of Helius Therapeutics Limited in New Zealand, Helius had products fully released and available in the Australian Market.
The New Zealand Medicinal Cannabis Scheme came into force in October 2021 and Helius Therapeutics was the first local producer to meet the stringent minimum quality standards required.
CEO, Carmen Doran said “We are very proud to see that just 3 years after our successful launch in New Zealand, we have been able to make our products available in Australia.
“This is a significant milestone in Helius’ growth made all the more significant being on the third anniversary of our first product launch. It’s great to now have our medicines available to Australian patients as well as our New Zealand patients”.
Helius Therapeutics has partnered with Novachem as the sponsor of the HTL products in Australia and has also made the products available through a number of key distributors including Cannabis Warehouse, The Entourage Effect and Leafio. This will enable quick, efficient access to the widest range of pharmacies.
Novachem Medical Products Manager, Andrew Heath echoed these sentiments: “Having seen first hand the quality of the facilities and the commitment to patient outcome, Novachem is confident that the HTL products will add substantial value to patients in Australia. Having these products tested in Australia to Australian standards adds an additional level of surety to prescribers and patients alike”.
